CASPER MARC N sold $172K of TMO

CASPER MARC N (Chairman & CEO) sold 275 shares of THERMO FISHER SCIENTIFIC INC. (TMO) at an average of $627.05 ($625.41–$628.74, $0.17M total) across 4 trades on 2026-08-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · CASPER MARC N
Published Aug 26, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 26, 2026, 8:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TMO
Neutral
medium confidence
Mentioned
$TMO
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TMONeutralLow
01

Why it matters

The disclosed sale is modest and pre‑arranged, suggesting limited immediate price impact.

02

Market read

Provides fresh insider transaction data for traders monitoring executive activity.

03

What to watch

Potential tax planning or portfolio rebalancing may drive the transaction, not company performance.

Relevance 3/10Novelty 4/10Timing: post‑market 2026-08-24

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$TMONeutralMedium confidence
Context

CEO Casper Marc N sold 275 shares for $172,438 via a 10b5-1 plan on 2026-08-24

Expected impact

Potential slight downward pressure, likely within normal volatility range

Evidence & confidence

The sale represents ~0.2% of the insider's post‑transaction holdings and is disclosed under a pre‑arranged plan, limiting immediate market reaction.

Market effects

Minimal impact on the life‑sciences equipment sector; insider sales are routine.

No significant regional effect; the filing is specific to Thermo Fisher.

Limited global relevance; only relevant to investors tracking Thermo Fisher.

Counterpoint

The sale could be unrelated to company outlook, as 10b5‑1 plans are pre‑scheduled.

Key entities

  • Thermo Fisher Scientific Inc.

    US‑listed life‑sciences equipment and services provider (ticker TMO).

  • Casper Marc N

    Chairman & CEO of Thermo Fisher Scientific.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TMOMed

Thermo Fisher Scientific Replenishes Buyback Capacity to $5 Billion

Thermo Fisher Scientific (TMO) authorized up to $5B in new stock repurchases, replacing a prior authorization with $1B remaining. The company spent $4B on buybacks in 2026's first nine months, with no purchases in Q3. Operating cash flow increased to $5.867B for the period, with $4.618B in free cash flow. The new authorization complements acquisitions, dividends, and debt obligations.